- Home
- ZTEK vs IMA Comparison
ZTEK vs IMA Comparison
Compare ZTEK & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZTEK | IMA |
|---|---|---|
| Founded | 2008 | 2019 |
| Country | Canada | United States |
| Employees | N/A | 15 |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.2M | 65.3M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZTEK | IMA |
|---|---|---|
| Price | $0.63 | $6.02 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 133.4K | 27.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $5.70 |
| 52 Week High | $1.84 | $17.50 |
Technical Indicators
Market Signals| Indicator | ZTEK | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 46.86 | 37.80 |
| Support Level | $0.55 | $5.97 |
| Resistance Level | $0.75 | $7.17 |
| Average True Range (ATR) | 0.05 | 0.34 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 69.90 | 12.02 |
Price Performance
Historical ComparisonAbout ZTEK Zentek Ltd.
Zentek Ltd is an IP development and commercialization company focused on next-gen healthcare solutions in the areas of prevention, detection, and treatment. It is focused on commercializing ZENGuard, a patent-pending coating with 99% antimicrobial activity, including against COVID-19, and the potential to use similar compounds as pharmaceutical products against infectious diseases.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.